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Brief Report
ABSTRACT
This bicentric study assessed retrospectively the usefulness of 18 F-FDG-PET in the staging of 31 patients with lymphocyte-predomi-
nant Hodgkin’s disease (LPHD). FDG-PET and conventional explorations (CE) were performed for initial disease (n=25) or recurrence
(n= 6). All the 68 involved sites were detected by PET including 5 extra-nodal lesions. Only 43 nodal sites (68%) and one splenic focus
were detected by CE. PET changed staging in 9 patients (7 upstaged, 2 downstaged) and radiation fields in 3 patients. These results
showed the potential role of PET in the staging of LPHD.
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Introduction
Lymphocyte predominant Hodgkin’s disease (LPHD) is a
rare and specific subtype of Hodgkin’s lymphoma (HL)1,2 in
most cases involving the lymph nodes, with limited extension
(Ann Arbor stage I or II) and an indolent outcome.3,4 This dis-
ease requires regular follow up due to the tendency toward
frequent relapses.4,5
No consensus has been yet established on the management
of LPHD, as chemotherapy,6 radiotherapy,7 immunotherapy,8
and watch and wait attitude are possible options.9
Positron emission tomography using 2-[18F]fluoro-2-deoxy-
D-glucose (FDG-PET) plays an important role in evaluation of
HL and non Hodgkin’s lymphoma (NHL), for staging and ther-
apy assessment.10,11
This study was conducted to assess the role of FDG-PET in
the management of LPHD.
Design and Methods
Patients
Among the 39 LPHD patients explored between July 2002
and May 2006, 31 (79%) were retrospectively included (25
men, 6 women, median age: 35 years, range 16-75) from the
hematology departments of Nantes and Rennes University
Hospitals. The diagnosis of LPHD was proven pathologically
by two independent pathologists according to REAL classifica-
tion1 either at the onset of the disease (n=25) or at relapse
(n=6). Five patients had previously been treated with ABVD
followed by involved field radiotherapy (IFRT) and one by sur-
gery followed by IFRT. 
Conventional explorations
Conventional explorations (CE) included medical history,
physical examination (lymph node >1 cm was suspected to be
pathological), laboratory screening, chest X-Ray, computed
tomography (CT) of neck, thorax, abdomen, pelvis with intra-
venous contrast enhancement, and neck (n=5) or abdomen
(n=9) ultrasound. A bone marrow biopsy was performed in 13
patients. 
CT was analyzed independently by two radiologists accord-
ing to classical criteria. CT size criteria for pathological lymph
nodes was a diameter >1.5 cm in cervical, axillary, mesenteric
and inguinal regions and >1.0 cm elsewhere. 
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FDG-PET imaging
Ten whole-body FDG-PET, prior to May 2004 in
Rennes, were performed with a GE Advance and 21
whole-body FDG-PET/CT with either a Discovery LS in
Nantes or a Discovery ST in Rennes (GE Medical
Systems, Milwaukee, WI, USA). PET was conducted 60
minutes after intravenous injection of 5 MBq/kg of 18F-
FDG. Patients fasted at least 6 hours and normogly-
caemia was established. The emission scan was acquired
after registration of CT or transmission scan with
Germanium 68 external ring source. The CT was used
for PET attenuation correction and for localization of the
foci. No contrast agent was administered. 
FDG-PET interpretation
FDG-PET images were reviewed by two experienced
nuclear medicine specialists, blinded to CE results.
Discrepancies in interpretation between observers were
resolved by consensus. Abnormal focal uptake was
defined as greater than background activity in bordering
tissue and not related to physiologic sites of tracer uptake
and abnormal splenic uptake as greater than in the liver.
Semi-quantitative analysis was performed using the
maximum standard uptake values (SUVmax) normalized
to body weight, of all abnormal foci. 
Imaging performance analysis and Gold standard
For both ethical and practical reasons, every suspected
involved lesions have not been evaluated by histology.
Gold standard was therefore determined on the basis of
histology and follow-up according to International
Workshop Criteria (IWC).12 When confirmation of
involvement was not possible by histology or follow-up,
a lesion detected only by one modality of CE or only by
FDG-PET was considered uncertain and not valuable to
modify the staging. True-positive (TP) corresponded to
an abnormal image on CE or FDG-PET confirmed by
histopathology or by follow-up as progression or
response after treatment according to IWC. A negative
finding on CE or FDG-PET was considered to be false-
negative (FN) if positive by histopathology or by 1 imag-
ing method plus follow-up. A false-positive (FP) was a
positive finding on CE and/or FDG-PET and negative
findings on histopathology or other imaging modalities
and follow-up (no progression or no response to treat-
ment). Sensitivity of CE or FDG-PET was determined on
an anatomic sites basis analysis. 
Results and Discussion
Patients and clinical outcome
A total number of 75 sites were involved and 7 periph-
eral nodal sites were fully removed before imaging. Sixty
eight sites were considered as involved according to gold
standard, allowing staging of 16 patients as Ann Arbor
stage I (5 patients with no residual lesion after surgery), 11
patients as stage II, 2 patients as stage III and 2 as stage IV. 
A watch and wait attitude was adopted for 14 patients
(45%). Seventeen patients (55%) received treatment:
chemotherapy (ABVD, n=2), rituximab (n=5), IFRT
(n=5), chemotherapy and radiotherapy (n=4) or
chemotherapy and rituximab (n=1). 
Conventional exams 
CE concluded to 44 involved sites, 43 peripheral lymph
nodes and one extra-nodal lesion (spleen) CE showed 3
FP in 3 patients: a differentiated thyroid carcinoma
pathologically proven, an inguinal node and a splenic
nodule confirmed as unspecific by follow-up. Sensitivity
of CE was 65%.
FDG-PET results
FDG-PET concluded to 68 involved sites , 63 nodal
sites and 5 extra-nodal sites. Six FP were displayed: bilat-
eral axillary and inguinal foci in a 16 year-old patient
with viral inflammation confirmed pathologically, 1 thy-
roid carcinoma pathologically proven and 1 splenic focus
not detected by US, MRI, CT and confirmed as unspecif-
ic by follow-up. FDG-PET and CE results were concor-
dant for 44 sites. FDG-PET revealed 20 additional nodal
sites, confirmed by follow-up and 4 additional extra-
nodal sites, in stomach and guts pathologically con-
firmed and in spleen and bones confirmed by follow-up.
Sensitivity of FDG-PET was 100%.
SUVmax of LPHD foci ranged from 1.2 to 20.1 (medi-
an= 6.1). In the 6 patients at relapse, SUVmax ranged
from 1.2 to 17.6 (median= 6.1). Mean SUVmax per
patient was equal to 9.5±4. Ten patients (32%) had at
least one lesion with a SUVmax > 10 (16 sites). 
Impact of FDG PET on Ann Arbor staging and treatment
Impact on Ann Arbor staging is summarized in Table 1.
As compared with CE, FDG-PET allowed upstaging in 7
patients (23%). For 2 patients with neck lesions, FDG-
PET revealed axillary and supraclavicular lesions, chang-
ing the stage I to stage II. In 2 patients with upper-
diaphragmatic relapse, FDG-PET led modification of
stage II to stage III showing small mesenteric nodes and
abnormal foci in the liver hilar region. Two patients
showed upstaging from stage III to stage IV with bone
(Figure 1) or stomach-intestine involvement detected by
FDG-PET.
Compared with CE, FDG-PET led to downstage 2
patients (6%). One patient was downstaged from stage
III to stage II: an inguinal node discovered by CT did not
show any uptake and remained unchanged after
immunotherapy and 2 year-follow up whilst other
upperdiaphragmatic nodes responded completely to
treatment according to IWC. The second one was down-
staged from stage III to stage I, in absence of abnormal
uptake on a 13 mm splenic lesion, stable 22 months after
initial US whilst IFRT was decided on the left cervical
lesion visualized by CT and FDG-PET.
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The treatment strategy was changed for 3 patients
(10%) based on FDG-PET findings, leading in extending
the radiotherapy fields for 2 patients, and in reducing
them for 1.
Over the last decade, FDG-PET has been considered as
an useful tool in the staging, therapeutic evaluation and
characterization of residual masses of HL13,14 and aggres-
sive NHL.15-16 FDG-PET has proven superior to CE in
detecting involved regions leading to changes in treat-
ment strategy in 15-25% of cases. A few cases of LPHD
have recently been reported in series exploring the role of
FDG-PET in the staging of HL.14,17 We report on a large
series of 31 LPHD patients explored by FDG-PET. 
FDG uptake appeared to be relatively intense since the
median SUVmax per sites was 6.1 with a wide intra and
inter-individual variation. Recently, Hutchings et al.
demonstrated a significant difference in FDG uptake
between the histological subtypes of HL,17 finding a
mean SUVmax of 8.3 in the 7 LPHD patients compared
with 11.2 for nodular sclerosis and 14.6 for mixed cellu-
larity patients. In the series of NHL of Schoder et al.,
SUVmax >10 excluded indolent lymphoma with 81%
specificity.18 Ten of our patients had a SUVmax >10.
None of them showed aggressive transformation to date. 
In our study, the staging using FDG-PET led to 22 con-
firmations (71%) and 9 modifications in the Ann Arbor
stage, with 7 upstaging (23%) and 2 downstaging (6%).
FDG-PET appeared to be superior to CE (in order) to
stage accurately LPHD at initial assessment. Several stud-
ies in HL patients have shown upstaging in 11-41% and
downstaging in 0-28% usingFDG-PET.13,14, 19,20
In our series, 3 modifications (10%) in the treatment
strategy according to FDG-PET results affected the extent
of radiotherapy fields. A recent report indicates a change
in therapeutic strategy in 9% of HL patients after consid-
ering the results of PET/CT.14
In conclusion, this retrospective study showed in a
large series of 31 patients that FDG-PET may be helpful
in the initial staging of LPHD. However, enhanced stag-
ing quality provided by FDG-PET will be valuable if
accompanied by a change in therapeutic strategy
towards less toxic and more individually tailored therapy
in this indolent disease.
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Figure 1. Patient upstaged from stage III to stage
IV, due to multiple bone uptake. Abnormal left iliac
bone focus. This patient had other bony foci (ribs,
vertebral column, right iliac bone…) and lymph
nodes foci (cervical, inguinal, iliac regions), increas-
ing in number and intensity on a second FDG-PET,
which all resolved after 2 cycles of chemotherapy
(ABVD).
Table 1. Impact of FDG-PET on final staging according to Ann
Arbor classification.
FDG-PET
Stage I Stage II Stage III Stage IV
Stage I 15 3 0 0
CE Stage II 0 7 2 0
Stage III 1 1 0 2
Stage IV 0 0 0 0
CE: conventional explorations.
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